The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations
about
Structural Basis for the Role of the K65R Mutation in HIV-1 Reverse Transcriptase Polymerization, Excision Antagonism, and Tenofovir ResistanceHIV-1 Reverse Transcriptase (RT) Polymorphism 172K Suppresses the Effect of Clinically Relevant Drug Resistance Mutations to Both Nucleoside and Non-nucleoside RT InhibitorsApricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutationsThe renaissance of fixed dose combinations: CombivirN348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistanceResistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysisHIV-1 drug resistance and resistance testing.Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western IndiaLow-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in NigeriaThe Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovirHIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naïve to HAART in Cameroon.A Leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus.Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitorsImmune-mediated attenuation of HIV-1HIV-1 antiretroviral drug therapy.Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in CameroonEvolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir.Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency.Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection.Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudineHIV-1 drug resistance mutations: an updated framework for the second decade of HAARTHypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model.Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2.The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug ResistanceManagement of paediatric HIV-1 resistance.Antiretroviral drug resistance in human immunodeficiency virus type 2.Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.The lysine 65 residue in HIV-1 reverse transcriptase function and in nucleoside analog drug resistance.Prevalence and dynamics of the K65R drug resistance mutation in HIV-1-infected infants exposed to maternal therapy with lamivudine, zidovudine and either nevirapine or nelfinavir in breast milk.Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.NRTI backbone in HIV treatment: will it remain relevant?
P2860
Q27657718-F0260616-10C3-4D28-B3D5-DEFD58CEC62CQ27670634-6A37C1C3-7630-4305-B660-31161B3FD74EQ28235418-0C632BAB-43CA-4DF2-9EBD-7CD802B90168Q28279752-E1203631-AA19-4F6E-861C-297860565C60Q28471689-AAC3FA4F-8798-4F7A-BFD7-6CD067733C19Q28478121-50050703-4A02-4EDA-B4BB-7CF6927EADC4Q30245693-444F141D-AEB0-48E4-AD77-1908F5BF6E05Q33595427-DDAA9507-D727-45EE-AB99-EC7AC677FAB0Q33602033-01595CB0-B0D9-49F2-ADDD-99F8D86D33C3Q33625367-AAB41F89-29F2-49EF-A18F-665362DF39D5Q33889635-8ECF6801-C579-4544-A1ED-97C8760FC40AQ33900459-F29E69F9-6270-40D8-84BC-9F4B5AFF59E7Q33927293-731A6CD5-BBCF-498D-8604-2BE284C88D89Q33959260-15FFBACA-5FF8-4E88-8D4F-338E56EDC691Q33985702-CC4E19DF-0E81-4B47-BDB1-4938E729735DQ34219941-7D071C25-02B2-4CD7-B15D-68E17789DF3DQ34573897-AEAF14E8-1B58-494C-BBB4-600570ABFAA3Q35635667-C56CD1E7-410F-48C4-855B-EB8D549FD2C1Q35798108-E11232BF-3B08-4586-B23F-CA9B76211D86Q35853012-D4EF4731-58B8-46B7-8AFF-DA58E8186BC9Q36276790-CE57A0E3-914F-42AD-8F9F-382E9704F88BQ36581795-4AA77AE0-1711-4190-B921-14753B9375D9Q36632238-729C3088-23FA-49DA-92C4-69B302F2ECCEQ36791067-A76BEB66-DC77-40FA-949C-70EB9B08D70CQ36836868-EF7B4F4B-8729-4037-AE1E-F4CCC2177071Q36852626-2FB85569-7248-41DA-8DBC-3495DF7870A5Q36900010-B18240ED-9992-47A4-95BD-59AB5A226C6BQ36964321-C0FE1C8F-65B2-41C4-8FA9-AE330E7F8DAFQ36993425-79A04C5E-628B-4393-88C7-BFA4F6E5BB4EQ37072022-F5E16A41-BA27-4986-A404-4EA4761217D8Q37288671-075B0F9D-21BE-42B9-BD92-9DAA2BAB7924Q37326138-23F7BC05-F22E-4653-BC06-C36908E8625DQ37496287-C99CFBFC-AFF3-420C-B978-2BD74F3EDD09Q37859395-B3599078-38EA-4665-9583-DF990A89270FQ38262356-C5B69948-B801-4E4C-894C-765E84110205Q38898319-4E5CBC2E-9768-46B8-A774-4FEE92E72DABQ38959269-D1D6C1D1-F074-45B8-9DDA-EE609B2EC964Q39043026-556B7ABE-3FE7-4856-9DA4-40D45A5E96D8Q39142877-68B6DC34-258A-4EAE-9761-80B11D528784Q39533858-C31FEB04-54B6-42F7-A0A4-8999A1A27050
P2860
The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The K65R mutation in human imm ...... ith thymidine analog mutations
@ast
The K65R mutation in human imm ...... ith thymidine analog mutations
@en
The K65R mutation in human imm ...... ith thymidine analog mutations
@nl
type
label
The K65R mutation in human imm ...... ith thymidine analog mutations
@ast
The K65R mutation in human imm ...... ith thymidine analog mutations
@en
The K65R mutation in human imm ...... ith thymidine analog mutations
@nl
prefLabel
The K65R mutation in human imm ...... ith thymidine analog mutations
@ast
The K65R mutation in human imm ...... ith thymidine analog mutations
@en
The K65R mutation in human imm ...... ith thymidine analog mutations
@nl
P2093
P2860
P1433
P1476
The K65R mutation in human imm ...... ith thymidine analog mutations
@en
P2093
Dianna Koontz
John W Mellors
Lee Bacheler
Urvi M Parikh
P2860
P304
P356
10.1128/JVI.80.10.4971-4977.2006
P407
P577
2006-05-01T00:00:00Z